The efficacy of the stereotactic body radiation in the management of the cholangiocarcinoma
PO-1301
Abstract
The efficacy of the stereotactic body radiation in the management of the cholangiocarcinoma
Authors: Ahmed Gawish1, Burkard Röllich1, Sebstian Senz1, Thomas B. Brunner1
1Medical Faculty University Hospital Magdeburg, University Clinic for Radiation Therapy, Magdeburg, Germany
Show Affiliations
Hide Affiliations
Purpose or Objective
We provide single-institution results for patients with non-resectable locally advanced cholangiocarcinoma, both with and without further neoadjuvant stereotactic body radiation treatment (SBRT) and chemotherapy.
Material and Methods
Twenty-two consecutive patients with extrahepatic or intrahepatic cholangiocarcinoma had SBRT and were retrospectively evaluated between October 2017 and June 2021. No patient was a candidate for a liver transplantation , however three patients underwent a complete resection after SBRT. SBRT was delivered in 12 fractions with a median dose of 60 Gy. The toxicity of each participant was rated using the CTC for Adverse Events. Using the Kaplan-Meier technique, overall survival (OS), time to progression, and local control were calculated.
Results
The median follow-up was 15 months (range 3-29 months). The actuarial 1 year local control rate was 85 %. The 2-year OS rates was 30 %, , with a median survival of 15.7 months. The 1- and 2-year freedom from progression was 68% and 45 %, respectively. Median time to progression was 13 months. 20 patients (90%) experienced some form of acute grade 1-2 toxicity, most commonly fatigue or pain. no patient experienced grade ≥3 toxicity.
Conclusion
When cholangiocarcinoma cannot be surgically removed or in recurrence situation after surgery, SBRT may be considered as an alternative treatment option. It may be used as part of neoadjuvant therapy or as part of definitive treatment in patients with cholangiocarcinoma.